14q1

Targeting Trends 2014 Newsletter

2014, issue 1: FDA Gives Green Light to Human Clinical Trials for Cancer Pain / by DA Lappi / featuring SP-SAP Targeting Talk: Time Course Targeting Tools: Investigating the Itch Pathway 2014, issue 2: Celebrating Twenty Years of Science Advanced Targeting Systems (founded 22 Apr 1994) / featuring 192-IgG-SAP, SP-SAP, Bombesin-SAP Celebrating Twenty Years of People Who Make ATS …

Targeting Trends 2014 Newsletter Read More »

Targeting Tools: Investigating the Itch Pathway

Bombesin-SAP (Cat. #IT-40) Bombesin is a 14-amino-acid peptide found in frog-skin. The human equivalent, gastrin releasing peptide (GRP) has been detected in itch pathways and plays a role in eating behaviors. GRP regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation. …

Targeting Tools: Investigating the Itch Pathway Read More »

Targeting Talk: Time Course

How long does it take to see the cell death occurring from the use of targeted toxins using saporin? Is there a time course of hours or days? The figure below illustrates the time course of cell death very effectively. Internalization and cytotoxicity of SP-SAP in primary cultures of neonatal spinal cord neurons (11). Confocal …

Targeting Talk: Time Course Read More »

Targeting Topics 14q1

BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer’s disease. Burke RM, Norman TA, Haydar TF, Slack BE, Leeman SE, Blusztajn JK, Mellott TJ. Proc Natl Acad Sci U S A 110(48):19567-19572, 2013. During development bone morphogenetic protein 9 (BMP9) induces the cholinergic phenotype in the basal forebrain. The authors investigated …

Targeting Topics 14q1 Read More »

Cover Article: FDA Gives Green Light to Human Clinical Trials for Cancer Pain

Contributed by Douglas A. Lappi, Ph.D., President/Chief Scientific Officer, Advanced Targeting Systems, San Diego, CA Substance P-Saporin (SP-SAP), ATS’s patented conjugate being developed for cancer pain therapy, has attracted a considerable amount of attention recently. Back-to-back publications, a press release and editorial were featured in the November issue of the journal Anesthesiology. The first article, …

Cover Article: FDA Gives Green Light to Human Clinical Trials for Cancer Pain Read More »